Sirolimus

證據等級: L5 預測適應症: 10

目錄

  1. Sirolimus
  2. Sirolimus: From Renal Transplant Rejection Prophylaxis to Liposarcoma
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. Denmark Market Information
    7. Safety Considerations
    8. Conclusion and Next Steps
    9. Disclaimer

## 藥師評估報告

Sirolimus: From Renal Transplant Rejection Prophylaxis to Liposarcoma

One-Sentence Summary

Sirolimus (rapamycin) is an mTOR inhibitor originally developed as an immunosuppressant to prevent organ rejection in renal transplantation. The TxGNN model predicts it may be effective for Liposarcoma, with 5 clinical trials and 12 publications currently supporting this direction — though most of the trial evidence comes from related mTOR inhibitors (temsirolimus, everolimus, ridaforolimus) rather than Sirolimus itself.


Quick Overview

Item Content
Original Indication Immunosuppression / prophylaxis of renal transplant rejection (well-established use; specific Danish regulatory indication text is not confirmed in the available data)
Predicted New Indication Liposarcoma
TxGNN Prediction Score 99.89%
Evidence Level L2
Denmark Market Status Not marketed
Number of Marketing Authorisations 0
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor (“rapalog”), a drug class whose efficacy in preventing renal transplant rejection is well established, and which mechanistically may be applicable to certain soft-tissue sarcomas.

Dedifferentiated liposarcoma frequently shows activation of the PI3K–Akt–mTOR signalling pathway (PMID 26518767), and mTOR inhibition can block this downstream proliferative signal — giving the prediction a clear molecular biology rationale. However, of the 5 clinical trials identified for this indication, only one (NCT02821507) uses Sirolimus itself directly; the remaining four involve related agents in the same drug class (temsirolimus, everolimus, ridaforolimus). This means the supporting evidence is largely a class-effect inference rather than direct, drug-specific proof for Sirolimus in liposarcoma.

It is also worth noting that among the other candidate indications generated for Sirolimus in this evidence pack (not detailed in this report), lymphangioleiomyomatosis (LAM) and PEComa/angiomyolipoma show substantially more direct, disease-specific Sirolimus evidence — including a completed Phase 3 RCT (NCT00414648, MILES trial) for LAM — and may warrant separate, higher-priority evaluation.


Clinical Trial Evidence

Trial Number Phase Status Enrollment Key Findings
NCT02821507 Phase 2 Completed 70 Single-arm trial of Sirolimus + cyclophosphamide in metastatic/unresectable myxoid liposarcoma and chondrosarcoma — direct use of Sirolimus itself, indication-matched
NCT00093080 Phase 2 Completed 216 Large trial of ridaforolimus (same-class mTOR inhibitor, not Sirolimus) in advanced sarcoma
NCT01614795 Phase 2 Completed 46 Cixutumumab + temsirolimus (same-class, not Sirolimus) in pediatric recurrent/refractory sarcoma
NCT00949325 Phase 1/2 Completed 24 Torisel (temsirolimus) + liposomal doxorubicin in advanced soft tissue and bone sarcoma
NCT03114527 Phase 2 Active, not recruiting 48 Ribociclib + everolimus (same-class) in advanced dedifferentiated liposarcoma and leiomyosarcoma

Literature Evidence

PMID Year Type Journal Key Findings
37967116 2024 Single-arm clinical trial report Clin Cancer Res Ribociclib + everolimus in dedifferentiated liposarcoma/leiomyosarcoma; synergistic mTOR/CDK4-pathway inhibition
26093731 2015 Cohort Transplantation Proceedings Cancer screening in renal transplant patients on long-term immunosuppression, including mTOR inhibitors
16434506 2006 Cohort J Am Soc Nephrol Sirolimus after early cyclosporine withdrawal reduced cancer risk vs. cyclosporine in renal transplant recipients
39796641 2024 Review Cancers Review of novel therapeutics in soft tissue sarcoma, including mTOR-pathway approaches
37222206 2023 Review Curr Opin Oncol Review of new targeted treatments for advanced sarcomas
20497911 2010 Review Bulletin du Cancer Review of targeted treatment strategies for rare connective tissue tumours and sarcomas by molecular subgroup
26518767 2016 Mechanism study Tumour Biology Analysis of 99 dedifferentiated liposarcoma specimens showing Akt/mTOR and MAPK pathway activation
37400145 2023 Preclinical Cancer Genomics Proteomics Chloroquine + rapamycin synergistically inhibits autophagy, effective in well-differentiated liposarcoma models
36309387 2022 Preclinical (PDX model) In Vivo Chloroquine + rapamycin arrests tumour growth in a patient-derived xenograft model of dedifferentiated liposarcoma
25519700 2015 Preclinical Mol Cancer Ther ATP-competitive mTOR kinase inhibitor MLN0128 shows antitumor activity in bone/soft-tissue sarcoma models

Denmark Market Information

Sirolimus is not currently marketed in Denmark — no national (Lægemiddelstyrelsen) or centralised (EMA) marketing authorisations are recorded in the evidence pack (0 licenses on file).


Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No drug interaction, warning, or contraindication data were available for review in this evidence pack.


Conclusion and Next Steps

Decision: Hold

Rationale:

  • Sirolimus is not currently marketed in Denmark, and a blocking data gap exists for SmPC warnings/contraindications, meaning an initial safety assessment cannot yet be performed.
  • Evidence for the liposarcoma indication specifically is class-effect based: only 1 of 5 trials uses Sirolimus itself directly, and the drug’s own original indication/MOA data could not be confirmed from available sources.

To proceed, the following is needed:

  • Obtain SmPC / product safety data (warnings, contraindications, drug interactions) from Lægemiddelstyrelsen or EMA
  • Confirm the drug’s approved original indication and mechanism of action via DrugBank or regulatory sources
  • Clarify access pathway given the drug is not marketed in Denmark (e.g., named-patient/off-label import)
  • Consider prioritizing evaluation of related predicted indications (lymphangioleiomyomatosis, PEComa/angiomyolipoma), where Sirolimus has more direct and mature supporting evidence than for liposarcoma

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Copyright © 2026 藥提醒科技有限公司 (yao.care). For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.